PetLife Pharmaceuticals, Inc.: 10-Q filed 2014-08-05
What PetLife Pharmaceuticals, Inc. reported in its quarterly report filed 2014-08-05 (fiscal Q2 2014): 20 published measures, 51 facts as tagged in accession 0001079974-14-000572.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-08-05
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001079974-14-000572 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PetLife Pharmaceuticals, Inc. filings.
Reported measures
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 704,076 | USD | |
| At 2013-02-28 | 697,600 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-09-01 to 2014-02-28 | -6,476 | USD | 181 |
| 2010-11-09 to 2014-02-28 | -5,519,607 | USD | 1208 |
| 2012-09-01 to 2013-02-28 | -647,214 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | -678,267 | USD | 1208 |
| 2012-09-01 to 2013-02-28 | -137,041 | USD | 181 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | 206,367 | USD | 1208 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | 884,634 | USD | 1208 |
| 2012-09-01 to 2013-02-28 | 137,030 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | -206,367 | USD | 1208 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-09-01 to 2014-02-28 | 468,501 | shares | 181 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | 1,933,074 | USD | 1208 |
| 2012-09-01 to 2013-02-28 | 298,248 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-12-01 to 2014-02-28 | -500 | USD | 90 |
| 2013-09-01 to 2014-02-28 | -1,000 | USD | 181 |
| 2010-11-09 to 2014-02-28 | -5,146,564 | USD | 1208 |
| 2012-12-01 to 2013-02-28 | -199,652 | USD | 90 |
| 2012-09-01 to 2013-02-28 | -659,434 | USD | 181 |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-12-01 to 2014-02-28 | 2,753 | USD | 90 |
| 2013-09-01 to 2014-02-28 | 5,476 | USD | 181 |
| 2010-11-09 to 2014-02-28 | 144,978 | USD | 1208 |
| 2012-12-01 to 2013-02-28 | 86,682 | USD | 90 |
| 2012-09-01 to 2013-02-28 | 88,922 | USD | 181 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 673,481 | USD | |
| At 2013-02-28 | 679,957 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-12-01 to 2014-02-28 | 500 | USD | 90 |
| 2013-09-01 to 2014-02-28 | 1,000 | USD | 181 |
| 2010-11-09 to 2014-02-28 | 5,146,564 | USD | 1208 |
| 2012-12-01 to 2013-02-28 | 199,652 | USD | 90 |
| 2012-09-01 to 2013-02-28 | 659,434 | USD | 181 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-12-01 to 2014-02-28 | 500 | USD | 90 |
| 2013-09-01 to 2014-02-28 | 1,000 | USD | 181 |
| 2010-11-09 to 2014-02-28 | 3,835,600 | USD | 1208 |
| 2012-12-01 to 2013-02-28 | 146,735 | USD | 90 |
| 2012-09-01 to 2013-02-28 | 553,651 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 563,170 | shares | |
| At 2013-02-28 | 563,170 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 4,881,457 | USD | |
| At 2013-02-28 | 4,881,457 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | -673,481 | USD | |
| At 2013-02-28 | -679,957 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 766,367 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-08-31 | 766,367 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-12-01 to 2014-02-28 | -3,253 | USD | 90 |
| 2013-09-01 to 2014-02-28 | -6,476 | USD | 181 |
| 2010-11-09 to 2014-02-28 | -5,519,607 | USD | 1208 |
| 2012-12-01 to 2013-02-28 | -197,492 | USD | 90 |
| 2012-09-01 to 2013-02-28 | -647,214 | USD | 181 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-11-09 to 2014-02-28 | 80,000 | USD | 1208 |
| 2012-09-01 to 2013-02-28 | 30,000 | USD | 181 |
Inspect the source
- Entity
- PetLife Pharmaceuticals, Inc. / CIK 0001354591
- Captured
- SEC response SHA-256
41a0ceb8f85d25ccf92688c1e58fdda5b8df53bc4f4e1ac81b38afabe0cc1efa
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001354591.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))